¼¼°èÀÇ °áÀý¼º °æÈ­Áõ Ä¡·áÁ¦ ½ÃÀå º¸°í¼­(2025³â)
Tuberous Sclerosis Drug Global Market Report 2025
»óǰÄÚµå : 1760733
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,263,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,052,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,842,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

°áÀý¼º °æÈ­Áõ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2029³â±îÁö ¿¬Æò±Õ 8.4%ÀÇ ¼ºÀå·ü(CAGR)·Î 11¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ¿¹»óµÇ´Â ¼ºÀåÀÇ ¿øµ¿·ÂÀº ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡, Èñ±ÍÁúȯ Ä¡·áÁ¦ °³¹ß ÅõÀÚ Áõ°¡, ȯÀÚ ¿ËÈ£ ¹× Áö¿ø ³×Æ®¿öÅ© È®´ë, Ä«³ªºñµð¿Ã ±â¹Ý Ä¡·á¹ýÀÇ ÃâÇö, À¯ÀüÀÚ Ç¥Àû Ä¡·áÀÇ ¹ßÀü µîÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£À» Çü¼ºÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÁÖ¿ä µ¿ÇâÀ¸·Î´Â º´¿ë¿ä¹ý Á¢±Ù¹ýÀÇ ¼ºÀå, Èñ±ÍÁúȯ Ä¡·áÁ¦ ±ÔÁ¦ ½Å¼ÓÈ­, Ä­³ªºñµð¿Ã(¿¡Çǵð¿Ã·º½º) äÅà Áõ°¡, Áúº´ º¯Çü Ä¡·á¹ý °³¹ß, °áÀý¼º °æÈ­Áõ º¹ÇÕü(TSC) °ü¸®¿¡ ÀÖ¾î µðÁöÅÐ Çコ ±â¼ú ÅëÇÕ µîÀÌ ÀÖ½À´Ï´Ù.

¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡´Â ÇâÈÄ ¸î ³â°£ °áÀý¼º °æÈ­Áõ Ä¡·áÁ¦ ½ÃÀå È®´ë¿¡ Å©°Ô ±â¿©ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¸¸¼ºÁúȯÀº ¼­¼­È÷ ¹ßº´Çϰí Áö¼ÓÀûÀÎ Ä¡·á°¡ ÇÊ¿äÇÑ Àå±âÀûÀÎ ÁúȯÀ» ¸»ÇÕ´Ï´Ù. ¿©±â¿¡´Â ´ç´¢º´, ½ÉÀ庴, °íÇ÷¾Ð, °üÀý¿°, ¸¸¼º È£Èí±â Áúȯ, ¾Ï, ºñ¸¸ µîÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ Áúº´ Áõ°¡´Â °Ç°­¿¡ ÇØ·Î¿î ½Ä½À°üÀ̳ª ¿îµ¿ ºÎÁ·°ú °°Àº »ýȰ½À°ü ¿äÀο¡ ±âÀÎÇÏ´Â ¹Ù°¡ Å©¸ç, Àå±âÀûÀÎ °Ç°­ ÇÕº´ÁõÀ» À¯¹ßÇÕ´Ï´Ù. °áÀý¼º °æÈ­Áõ Ä¡·áÁ¦´Â °áÀý¼º °æÈ­Áõ º¹ÇÕü(TSC)ÀÇ ±Ùº» ¿øÀÎÀ» ÇØ°áÇϰí Á¾¾ç ¾ïÁ¦ ¹× ¹ßÀÛ Á¶ÀýÀ» À§ÇÑ È¿°úÀûÀÎ ¿É¼ÇÀ» Á¦°øÇÔÀ¸·Î½á ¸¸¼º Áúȯ °ü¸®¸¦ Áö¿øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¾à¹°Àº Àå±âÀûÀÎ Áõ»ó °ü¸®¸¦ °¡´ÉÇÏ°Ô ÇÏ°í º´¿ø ¹æ¹® ºóµµ¸¦ ÁÙ¿© ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 6¿ù ¿µ±¹ ±¹¹Îº¸°Ç¼­ºñ½º(NHS)´Â ÀÏ¹Ý °³¾÷ÀÇ¿¡ µî·ÏµÈ ȯÀÚ Áß 2023³â ºñ´ç´¢º´¼º °íÇ÷´çÁõ ¶Ç´Â ´ç´¢º´ ¿¹ºñ±ºÀ¸·Î Áø´Ü¹ÞÀº ȯÀÚ°¡ 361¸¸ 5,330¸íÀ¸·Î 2022³â 306¸¸ 5,825¸í¿¡¼­ 18% Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù. °á°úÀûÀ¸·Î ¸¸¼ºÁúȯ À¯º´·ü Áõ°¡°¡ °áÀý¼º °æÈ­Áõ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

°áÀý¼º °æÈ­Áõ Ä¡·áÁ¦ ½ÃÀåÀÇ ±â¾÷µéÀº Æ÷À¯·ù ¶óÆÄ¸¶À̽ŠǥÀû(mTOR) ¾ïÁ¦Á¦ µî Á¾¾ç Ãà¼Ò, ¹ßÀÛ ¾ïÁ¦, ±Ùº»ÀûÀÎ Áúº´ ±âÀü ±Ô¸íÀ» ¸ñÇ¥·Î ÇÏ´Â Ä¡·áÁ¦ °³¹ßÀ» ÅëÇØ Çõ½Å¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ÇÏ´Â mTOR ´Ü¹éÁúÀ» Â÷´ÜÇÏ´Â ÀǾàǰÀÇ ÀÏÁ¾ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 8¿ù ¹Ì±¹ Á¦¾à»ç Upsher-Smith Laboratories LLC´Â °áÀý¼º °æÈ­Áõ º¹ÇÕü(TSC) ȯÀÚ¸¦ À§ÇØ 2.5mg, 5mg, 7.5mg, 10mgÀÇ ´Ù¾çÇÑ °­µµÀÇ TORPENZ(¿¡¹ö·Î¸®¹«½º) Á¤Á¦¸¦ Ãâ½ÃÇß½À´Ï´Ù. Åä¸£ÆæÁî´Â TSC¿¡¼­ ºñÁ¤»óÀûÀÎ ¼¼Æ÷ Áõ½ÄÀ» À¯¹ßÇÏ´Â °úµµÇÑ mTOR °æ·Î¸¦ ¾ïÁ¦ÇÏ¿© ¾ç¼º Á¾¾çÀ» Ãà¼ÒÇϰí, ¹ßÀÛ µî °ü·Ã Áõ»óÀ» Á¶ÀýÇÏ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ª ÀüÀï°ú °ü¼¼, ±×¸®°í ÄڷγªÀç³­°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Tuberous sclerosis drugs are medications used to treat the symptoms of tuberous sclerosis complex (TSC), a genetic disorder that leads to the formation of benign tumors in various organs, particularly the brain, kidneys, heart, lungs, and skin. The primary objective of these treatments is to reduce tumor size, control seizures, and manage related symptoms, ultimately enhancing the quality of life by addressing the underlying cellular abnormalities.

The main classes of drugs used in tuberous sclerosis treatment include targeted therapy, immunotherapy, and symptomatic treatments. Targeted therapy involves using medications that specifically focus on molecular pathways responsible for tumor growth in TSC. These drugs can be administered through various routes, including oral, intravenous, and subcutaneous methods. Treatment generally occurs in stages, such as initial diagnosis, chronic management, and management of recurrent symptoms. Distribution occurs through hospital pharmacies, retail pharmacies, and online pharmacies, with end-users including hospitals, home care providers, specialty clinics, and others.

The tuberous sclerosis drug market research report is one of a series of new reports from The Business Research Company that provides tuberous sclerosis drug market statistics, including tuberous sclerosis drug industry global market size, regional shares, competitors with a tuberous sclerosis drug market share, detailed tuberous sclerosis drug market segments, market trends and opportunities, and any further data you may need to thrive in the tuberous sclerosis drug industry. This tuberous sclerosis drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tuberous sclerosis drug market size has grown strongly in recent years. It will grow from $0.79 billion in 2024 to $0.86 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth observed during the historic period can be attributed to the increasing awareness of rare genetic disorders, the rising prevalence of epilepsy among tuberous sclerosis complex (TSC) patients, higher rates of clinical diagnosis, the availability of anticonvulsants, and expanding research on neurocutaneous syndromes.

The tuberous sclerosis drug market size is expected to see strong growth in the next few years. It will grow to $1.19 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The anticipated growth in the forecast period is expected to be driven by a greater focus on personalized medicine, increased investment in the development of drugs for rare diseases, the expansion of patient advocacy and support networks, the emergence of cannabidiol-based treatments, and the progress in gene-targeted therapies. Key trends expected to shape the forecast period include the growth of combination therapy approaches, regulatory fast-tracking for rare disease drugs, rising adoption of cannabidiol (Epidiolex), the development of disease-modifying therapies, and the integration of digital health technologies in the management of tuberous sclerosis complex (TSC).

The growing incidence of chronic diseases is expected to significantly contribute to the expansion of the tuberous sclerosis drug market in the coming years. Chronic diseases are long-lasting medical conditions that usually develop gradually and require continuous care. These include diabetes, heart disease, hypertension, arthritis, chronic respiratory conditions, cancer, and obesity. The rise in these diseases is largely attributed to lifestyle factors such as unhealthy diets and physical inactivity, which lead to long-term health complications. Tuberous sclerosis drugs support chronic disease management by addressing the root causes of tuberous sclerosis complex (TSC), offering effective options for tumor suppression and seizure control. These medications improve patient outcomes by enabling long-term symptom management and reducing the frequency of hospital visits. For instance, in June 2024, the UK's National Health Service (NHS) reported that 3,615,330 individuals registered with general practitioners were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023-an 18% increase from 3,065,825 cases in 2022. As a result, the increasing incidence of chronic diseases is propelling the growth of the tuberous sclerosis drug market.

Companies in the tuberous sclerosis drug market are focusing on innovation through the development of treatments such as mammalian target of rapamycin (mTOR) inhibitors to reduce tumor size, control seizures, and target the underlying disease mechanisms. mTOR inhibitors are a class of medications that block the mTOR protein, which regulates key cellular processes including growth, proliferation, and survival. For example, in August 2024, Upsher-Smith Laboratories LLC, a U.S.-based pharmaceutical firm, introduced TORPENZ (everolimus) tablets in multiple strengths-2.5 mg, 5 mg, 7.5 mg, and 10 mg-for patients with tuberous sclerosis complex (TSC). TORPENZ functions by inhibiting the overactive mTOR pathway responsible for abnormal cell growth in TSC, helping to shrink benign tumors and manage associated symptoms such as seizures.

In February 2025, Immedica Pharma AB, a Sweden-based pharmaceutical company, acquired Marinus Pharmaceuticals Inc. for $151 million. This acquisition aims to expand Immedica's footprint in the rare seizure disorder segment and enhance its neuroscience drug portfolio, particularly with the inclusion of ganaxolone. The move supports Immedica's strategic objective to broaden its global presence and strengthen its pipeline for treating rare central nervous system (CNS) conditions. Marinus Pharmaceuticals Inc., based in the U.S., is a biopharmaceutical company focused on developing innovative therapies for rare seizure disorders, including those linked to tuberous sclerosis.

Major players in the tuberous sclerosis drug market are Johnson & Johnson, Novartis AG, The Johns Hopkins University, Yale University, Jazz Pharmaceuticals Public Limited Company, Washington University School of Medicine, Dr. Reddy's Laboratories, H. Lundbeck A/S, Shijiazhuang Yiling Pharmaceutical Co. Ltd, BridgeBio Pharma Inc., Globela Pharma Pvt Ltd., Noema Pharma AG, Aucta Pharmaceuticals Inc., Aeovian Pharmaceuticals Inc., Anavex Life Sciences Corp., Aucta Pharmaceuticals Inc., Par Pharmaceutical, GRIN Therapeutics Inc., Ovid Therapeutics Inc., and Cassava Sciences Inc.

North America was the largest region in the tuberous sclerosis drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tuberous sclerosis drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tuberous sclerosis drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tuberous sclerosis drug market consists of sales of topical treatments, psychiatric medications, and supportive care therapies used to manage the various symptoms and complications of tuberous sclerosis complex. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tuberous Sclerosis Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tuberous sclerosis drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for tuberous sclerosis drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tuberous sclerosis drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Tuberous Sclerosis Drug Market Characteristics

3. Tuberous Sclerosis Drug Market Trends And Strategies

4. Tuberous Sclerosis Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Tuberous Sclerosis Drug Growth Analysis And Strategic Analysis Framework

6. Tuberous Sclerosis Drug Market Segmentation

7. Tuberous Sclerosis Drug Market Regional And Country Analysis

8. Asia-Pacific Tuberous Sclerosis Drug Market

9. China Tuberous Sclerosis Drug Market

10. India Tuberous Sclerosis Drug Market

11. Japan Tuberous Sclerosis Drug Market

12. Australia Tuberous Sclerosis Drug Market

13. Indonesia Tuberous Sclerosis Drug Market

14. South Korea Tuberous Sclerosis Drug Market

15. Western Europe Tuberous Sclerosis Drug Market

16. UK Tuberous Sclerosis Drug Market

17. Germany Tuberous Sclerosis Drug Market

18. France Tuberous Sclerosis Drug Market

19. Italy Tuberous Sclerosis Drug Market

20. Spain Tuberous Sclerosis Drug Market

21. Eastern Europe Tuberous Sclerosis Drug Market

22. Russia Tuberous Sclerosis Drug Market

23. North America Tuberous Sclerosis Drug Market

24. USA Tuberous Sclerosis Drug Market

25. Canada Tuberous Sclerosis Drug Market

26. South America Tuberous Sclerosis Drug Market

27. Brazil Tuberous Sclerosis Drug Market

28. Middle East Tuberous Sclerosis Drug Market

29. Africa Tuberous Sclerosis Drug Market

30. Tuberous Sclerosis Drug Market Competitive Landscape And Company Profiles

31. Tuberous Sclerosis Drug Market Other Major And Innovative Companies

32. Global Tuberous Sclerosis Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Tuberous Sclerosis Drug Market

34. Recent Developments In The Tuberous Sclerosis Drug Market

35. Tuberous Sclerosis Drug Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â